All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the GvHD Hub spoke to Antonio Galleu, King's College London, London, UK. We asked: What factors impact response to mesenchymal stromal cells in patients with acute GvHD?
Influencing factors include prognostic markers identified prior to infusion, characteristic molecular changes observed during or following mesenchymal stromal cell treatment, or characteristics of the treatment itself. Here, Antonio Galleu discusses the key determinants of patient outcome to mesenchymal stromal cell infusion.
What factors impact response to mesenchymal stromal cells in patients with acute GvHD?
Subscribe to get the best content related to GvHD delivered to your inbox